Outcome Capital
Outcome Capital is a privately held Boston-based investment banking and strategic advisory firm serving middle-market growth companies in life sciences and healthcare, providing M&A advisory, capital raising, and strategic advisory through a scientist-banker team with PhD-trained Managing Directors and Big Pharma operating experience.
- Company typePrivate
- Founded2000
- HeadquartersReston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Outcome Capital does
Outcome Capital, LLC is a privately held investment banking and strategic advisory firm headquartered in Boston, Massachusetts, with a secondary office in Charlotte, North Carolina. Founded around 1998-2000 and registered with the SEC as a broker-dealer and FINRA/SIPC member, the firm operates as an affiliate of Outcome Holdings, LLC and focuses exclusively on middle-market growth companies in the life sciences and healthcare sectors, spanning biotech, diagnostics, medical devices, pharmaceuticals, healthcare IT, digital health, pharma services, and healthcare services. Its service platform combines investment banking (M&A advisory, capital raising, value creation, value realization) with strategic and financial advisory, delivered through dedicated industry practices and supported by content such as the Life Sciences Pulse monthly newsletter.
The firm differentiates itself through a scientist-banker model: most Managing Directors and Vice Presidents hold PhDs or CFA credentials with prior operating roles at major pharmaceutical and medical device companies including Novartis, Pfizer, Bayer, Johnson & Johnson, Schering-Plough, and Becton-Dickinson. Notable closed transactions include the $175M Propella Therapeutics acquisition by Astellas Pharma, the $120M GenePOC acquisition by Meridian Bioscience, a $32M Elios Vision growth equity financing, the ZIEN Medical/Averra Holdings merger, and the RealizedCare/XRHealth acquisition, among others spanning 2016-2025.
Outcome Capital earns revenue primarily through success fees paid by issuers upon closing of M&A and capital raising mandates, supplemented by fees from private placement of securities to qualified institutional investors. Pricing is not publicly disclosed; fee percentages are pre-determined per engagement and vary by transaction. The firm has no productized software, AI/ML, or technology platform; its offering is advisory labor and relationship-based deal execution, with recent expansion in 2025-2026 via the Healthcare Services Practice, the Pharmacy and Related Services Advisory Board, and an ophthalmology practice led by a new senior hire.
Outcome Capital firmographics
Firmographics- Name
- Outcome Capital
- Legal name
- Outcome Capital, LLC
- Website
- https://outcomecapital.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Outcome Capital is a privately held Boston-based investment banking and strategic advisory firm serving middle-market growth companies in life sciences and healthcare, providing M&A advisory, capital raising, and strategic advisory through a scientist-banker team with PhD-trained Managing Directors and Big Pharma operating experience.
- Ownership category
- akta.pro rank
Outcome Capital industry classification
Industry- Product category
- Investment Banking and Strategic Advisory
- NAICS
- Investment Banking and Securities Intermediation (523150), Investment Banking and Securities Intermediation (52315)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
- akta.pro primary industry
- Corporate Finance & Capital Advisory (BPAHADAB)
- akta.pro secondary industries
- Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG), Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG), Corporate Finance Advisory (Strategic Finance, Capital Structure & Recaps) (FSAEAGAE)
Keywords
Where Outcome Capital is headquartered
LocationHeadquarters
- HQ city
- Reston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Outcome Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Success Fees on Advisory Transactions: Primary revenue derived from pre-determined percentage of fees paid by issuers upon successful transaction completion. Works with multiple issuers and fees vary by each engagement.
- Private Placement Securities: Acts as broker-dealer offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Success fee model based on transaction value |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Outcome Capital product offering
Product offeringCore offering
Outcome Capital provides investment banking and strategic advisory services to middle-market growth companies in the life sciences and healthcare sectors. Its core offerings include M&A advisory, capital raising (equity financing and private placements), strategic advisory, and financial advisory, delivered through a scientist-banker model that pairs PhD-trained professionals with deep sector expertise. The firm is an SEC-registered broker-dealer and FINRA member, enabling it to act as exclusive strategic and financial advisor on transactions such as mergers, acquisitions, licensing deals, and growth equity financings.
Product overview
Outcome Capital offers a unified advisory platform combining investment banking and strategic advisory services for middle-market growth companies in the life sciences and healthcare sectors. The firm operates two core service lines: Investment Banking (encompassing M&A advisory, capital raising, value creation, and value realization) and Advisory (including strategic and financial advisory). These services are delivered through specialized industry practices covering Life Sciences (Biotech, Diagnostics, Medical Devices, Pharmaceuticals) and Healthcare (Healthcare IT, Digital Health, Pharma Services, Healthcare Services), with dedicated offerings like the Pharmacy and Related Services Advisory Board and Healthcare Services Practice providing sector-specific strategic expertise. The firm positions itself as a strategic partner helping clients move innovations from development through commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Investment Banking Strategic investment banking services including M&A advisory, capital raising, value creation, and value realization for middle-market growth companies in life sciences and healthcare.
- Strategic Advisory Strategic advisory services focused on helping companies navigate market dynamics, optimize positioning, and develop market-driven strategies for M&A and financing transactions.
- Financial Advisory Financial advisory services including transaction structuring, valuation analysis, and financing support for life sciences and healthcare transactions.
- Life Sciences Practice Advisory and investment banking services serving the Biotech, Diagnostics, Medical Devices, and Pharmaceutical Industries.
- Healthcare Practice Advisory and investment banking services serving Healthcare IT, Digital Health, Pharma Services, and Healthcare Services industries.
- Healthcare Services Practice Dedicated practice area expanding strategic advisory and investment banking capabilities specifically focused on the Healthcare Services sector.
- Pharmacy and Related Services Advisory Board Advisory board providing strategic expertise for clients navigating changes in the pharmacy sector, focusing on innovation, regulation, and technology, and helping clients capitalize on market disruptions and technological advances.
- Value Creation Investment banking value creation services within the Investment Banking service line, focused on enhancing company value prior to transaction events.
- Value Realization Investment banking value realization services within the Investment Banking service line, focused on executing liquidity events including M&A exits, IPOs, and strategic transactions.
- Private Placement of Securities Broker-dealer service offering private placement of securities to qualified institutional investors on behalf of issuers raising capital through private placements exempt from registration.
Quantifiable outcome
- Value added 10x greater than value invested in services per client testimonial
- +1 more outcomes
Companies that use Outcome Capital
Customer profileNamed customers14 records
Segments3 records
Ideal customer profiles2 records
Outcome Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Outcome Capital partnerships and signals
Strategic signalScale indicators3 records
Recent moves8 records
Expansion highlights6 records
Outcome Capital competitors and assessment
Company assessmentDirect peers
- Piper Sandler: Piper Sandler operates one of the most active healthcare and life sciences investment banking practices among US middle-market banks, providing M&A advisory, capital raising, and equity research to biotech, medtech, and healthcare services companies — directly comparable to Outcome Capital's core offering and middle-market focus.
- H.C. Wainwright & Co. H.C. Wainwright is a boutique investment bank specializing in healthcare and life sciences with deep biotech equity placement and advisory capabilities. Its biotech-focused DNA, broker-dealer placement activity, and middle-market client base make it a close comparable to Outcome Capital.
- Jefferies (Healthcare Group): Jefferies runs a large global healthcare investment banking franchise covering biotech, medtech, and pharma services with M&A and capital markets capabilities. Its middle-market healthcare advisory footprint and placement agent activity overlap directly with Outcome Capital's service mix.
- Oppenheimer & Co. (Healthcare): Oppenheimer's Healthcare Investment Banking group provides M&A advisory and capital raising for life sciences and healthcare services companies across the middle market — a comparable boutique-style franchise competing for the same issuer mandates as Outcome Capital.
- Canaccord Genuity (Healthcare): Canaccord Genuity's healthcare investment banking group focuses on growth-stage biotech, medtech, and digital health M&A and equity financings. Its niche specialization and middle-market life sciences focus closely mirror Outcome Capital's positioning.
- Guggenheim Partners (Healthcare IB): Guggenheim Securities operates a healthcare investment banking franchise advising on M&A, equity, and debt financings for life sciences companies — directly comparable in client base, deal types, and middle-to-upper-middle market positioning to Outcome Capital.
- Wedbush Securities: Wedbush's Healthcare Investment Banking group covers biotech, medtech, and digital health M&A and capital raising. Its boutique orientation and life sciences focus align closely with Outcome Capital's service model and target issuer base.
- SVB Securities (Healthcare): SVB Securities built a healthcare-focused investment banking franchise advising biotech, medtech, and healthcare technology clients on IPOs, follow-ons, and M&A. Its vertical specialization and growth-stage client base overlap with Outcome Capital's middle-market life sciences focus.
- Raymond James (Healthcare IB): Raymond James' Healthcare Investment Banking group advises on M&A, equity, and debt financings for life sciences, medical devices, and healthcare services companies. Its middle-market focus and broad life sciences coverage make it a relevant comparable.
- Ladenburg Thalmann (Healthcare): Ladenburg Thalmann operates a healthcare and life sciences investment banking practice focused on middle-market advisory and capital raising. Its boutique scale and life sciences vertical emphasis closely parallel Outcome Capital's profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Outcome Capital social profiles
Digital presenceOutcome Capital compliance and trust
Trust signalCompliance2 records
Outcome Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Outcome Capital leadership team
Management profileNumber of profiles
Profiles20 records
Outcome Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Outcome Capital M&A and investment
M&A and investmentM&A1 record
Investments10 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Outcome Capital
What does Outcome Capital do?
Outcome Capital provides investment banking and strategic advisory services to middle-market growth companies in the life sciences and healthcare sectors. Its core offerings include M&A advisory, capital raising (equity financing and private placements), strategic advisory, and financial advisory, delivered through a scientist-banker model that pairs PhD-trained professionals with deep sector expertise. The firm is an SEC-registered broker-dealer and FINRA member, enabling it to act as exclusive strategic and financial advisor on transactions such as mergers, acquisitions, licensing deals, and growth equity financings.
Is Outcome Capital a public or private company?
Outcome Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Outcome Capital founded?
Outcome Capital was founded in 2000. It employs 11 to 50 people.
Where is Outcome Capital based?
Outcome Capital is headquartered in Reston, United States, in the North America region.
How does Outcome Capital make money?
Two revenue lines are on record. Success Fees on Advisory Transactions are the primary driver. The others are private Placement Securities.
Who are Outcome Capital's main competitors?
Direct peers on record are Piper Sandler, H.C. Wainwright & Co., Jefferies (Healthcare Group), Oppenheimer & Co. (Healthcare), Canaccord Genuity (Healthcare), Guggenheim Partners (Healthcare IB), Wedbush Securities, SVB Securities (Healthcare), Raymond James (Healthcare IB) and Ladenburg Thalmann (Healthcare).
Does Outcome Capital have an API?
No public API is recorded for Outcome Capital.
What industry is Outcome Capital in?
Outcome Capital's product category is Investment Banking and Strategic Advisory. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523150 and its SIC code is 6211.